Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives

Despite the application of conventional therapies, the prognosis of advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer therapy. Emerging evidence support the feasibility of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhening, Xie, Tong, Zhang, Xiaotian, Qi, Changsong, Shen, Lin, Peng, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369180/
https://www.ncbi.nlm.nih.gov/pubmed/32694895
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.02

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369180/
https://www.ncbi.nlm.nih.gov/pubmed/32694895
http://dx.doi.org/10.21147/j.issn.1000-9604.2020.03.02

Ejemplares similares